GURU.Markets stock price, segment price, and overall market index valuation
The company's share price ESSA Pharma Inc.
The stock price of ESSA Pharma, an oncology biotech, reflects the potential of its prostate cancer drugs. The price chart is a classic biotech story, with the price determined by expectations of clinical trial results.
Share prices of companies in the market segment - Cancer women
ESSA Pharma is a pharmaceutical company focused on developing prostate cancer drugs that block the N-terminal domain of the androgen receptor. We have classified it under "Cancer in Women" (categorization error). The graph below shows the dynamics of the prostate cancer treatment sector.
Broad Market Index - GURU.Markets
ESSA Pharma is a pharmaceutical company focused on developing drugs for the treatment of prostate cancer. Its unique approach makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how ESSA compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
EPIX - Daily change in the company's share price ESSA Pharma Inc.
ESSA Pharma Inc.'s daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its prostate cancer drugs.
Daily change in the price of a set of shares in a market segment - Cancer women
ESSA Pharma is a biotech company focused on prostate cancer, which results in high volatility. The chart below shows the average daily risk in this oncology segment. It serves as a benchmark for assessing how sensitive EPIX shares are to clinical trial news.
Daily change in the price of a broad market stock, index - GURU.Markets
ESSA Pharma is a biotech company focused on men's health, specifically cancer treatment. Its shares are highly volatile and dependent on clinical trial results. These scientifically based movements are part of a complex picture of the overall stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization ESSA Pharma Inc.
ESSA Pharma Inc.'s year-to-date performance is a story of developing a new approach to prostate cancer treatment. Its 12-month market capitalization is entirely dependent on clinical trial data from its drug, which targets the N-terminal domain of the androgen receptor. Success could offer new hope for patients with a resistant form of the disease.
Annual dynamics of market capitalization of the market segment - Cancer women
ESSA Pharma Inc. is a clinical-stage biotech developing drugs for the treatment of prostate cancer. Its stock price is entirely dependent on the results of clinical trials. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
ESSA Pharma is a biotech company whose value is tied to the hope of developing a new drug for prostate cancer. Its year-over-year performance relative to the market isn't a reflection of business processes, but a speculative bet on laboratory success. Its chart is a series of sharp movements driven by news.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization ESSA Pharma Inc.
ESSA Pharma is a clinical-stage oncology company. Its monthly performance is entirely dependent on the results of its clinical trials. Data on its prostate cancer drug is a key event, generating strong investor reaction.
Monthly dynamics of market capitalization of the market segment - Cancer women
ESSA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of drugs for the treatment of prostate cancer. Its sector dynamics, shown in the chart, reflect the risks of R&D. Against this backdrop, it is possible to assess how its unique approach, targeting the N-terminal domain of the androgen receptor, is progressing in clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
ESSA Pharma is a biotech company focused on prostate cancer. Its shares are buoyed by anticipation of clinical trial results. Their monthly performance is completely disconnected from the broader market, as the chart clearly illustrates, showing a reaction to scientific data rather than general economic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization ESSA Pharma Inc.
ESSA Pharma is an oncology company developing drugs for the treatment of prostate cancer. Its weekly stock price is volatile and depends entirely on the results of clinical trials of its innovative approach.
Weekly dynamics of market capitalization of the market segment - Cancer women
ESSA Pharma Inc. develops drugs to treat prostate cancer. The chart helps separate the stock's unique reaction to clinical trial news from the overall sentiment in the oncology sector. Is the weekly price movement specific to ESSA Pharma or is it an industry trend?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
ESSA Pharma Inc. is an oncology biotech company. Its success depends on scientific breakthroughs. The chart clearly shows how often the company's shares move against the broader market in response to research data releases. How immune is it to overall market volatility?
Market capitalization of the company, segment and market as a whole
EPIX - Market capitalization of the company ESSA Pharma Inc.
The ESSA Pharma chart shows a bet on a new approach to prostate cancer treatment. This biotech company's market cap reflects investors' faith in its experimental drug, which targets a specific protein. This is a highly volatile curve of scientific research and clinical trials.
EPIX - Share of the company's market capitalization ESSA Pharma Inc. within the market segment - Cancer women
ESSA Pharma is a biopharmaceutical company specializing in the development of drugs for the treatment of prostate cancer. Its market capitalization in the oncology segment for women (and men) reflects its narrow but important focus. The company's weight reflects the success of its innovative approach to treating this common disease.
Market capitalization of the market segment - Cancer women
ESSA Pharma is developing drugs to treat prostate cancer. How big is this arena? The graph below shows the pulse of the women's cancer treatment sector (by category), but focuses on oncology. Its dynamics map the hopes and risks in the search for new, more effective treatments for hormone-dependent tumors.
Market capitalization of all companies included in a broad market index - GURU.Markets
The ESSA Pharma chart shows how the market is pricing in the development of next-generation prostate cancer drugs. The company's market value is based on its unique approach to blocking the N-terminal domain of the androgen receptor. This chart is fraught with scientific risk, but has the potential to change the standard of care.
Book value capitalization of the company, segment and market as a whole
EPIX - Book value capitalization of the company ESSA Pharma Inc.
The book value of ESSA Pharma, an oncology company, is its tangible asset base, consisting of rights to drug candidates and financial reserves for clinical trials in prostate cancer treatment. The chart below shows how this scientific and financial capital has changed.
EPIX - Share of the company's book capitalization ESSA Pharma Inc. within the market segment - Cancer women
ESSA Pharma Inc. is a pharmaceutical company whose tangible assets are research laboratories focused on developing prostate cancer drugs. These R&D centers are its physical base for innovation. The chart shows the share of this specialized scientific infrastructure the company controls.
Market segment balance sheet capitalization - Cancer women
ESSA Pharma is an oncology company. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. ESSA focuses on drug development, and its capital lies in its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
ESSA Pharma's assets are not plants, but capital and a scientific platform focused on developing a new class of drugs that block the N-terminal domain of the androgen receptor for the treatment of prostate cancer. These assets reflect its financial resources for this research.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - ESSA Pharma Inc.
ESSA Pharma is a biotech company developing drugs to treat prostate cancer. Its market capitalization reflects its unique scientific approach. The chart shows how investors are reacting to clinical data in this important area of oncology.
Market to book capitalization ratio in a market segment - Cancer women
ESSA Pharma is a biotech company developing drugs to treat prostate cancer. Its value depends on the success of its lead drug. The chart shows how investors assess the scientific potential of its unique approach to treating this disease.
Market to book capitalization ratio for the market as a whole
ESSA Pharma is an oncology company focused on prostate cancer. Its entire value lies in its unique scientific approach and patents. This chart illustrates how, in biotech, market valuation reflects the potential of a single drug to change the standard of care and capture a multi-billion dollar market.
Debts of the company, segment and market as a whole
EPIX - Company debts ESSA Pharma Inc.
ESSA Pharma is a biopharmaceutical company focused on developing drugs for the treatment of prostate cancer. Oncology research requires significant and long-term investment. This chart shows how the company raises capital to fund its highly specialized, but very expensive, clinical trials and research.
Market segment debts - Cancer women
ESSA Pharma is a clinical-stage oncology company developing drugs for the treatment of prostate cancer. Its future depends on the results of clinical trials. This chart shows its cash reserves and how long it can fund its R&D.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio ESSA Pharma Inc.
ESSA Pharma is a clinical-stage biopharmaceutical company specializing in prostate cancer. This chart shows its financial structure. For a company whose future depends on the success of a single key drug, debt is a huge risk that could wipe out the company's value if it fails.
Market segment debt to market segment book capitalization - Cancer women
ESSA Pharma is a biopharmaceutical company developing a new generation of drugs for the treatment of prostate cancer. This market is large but competitive. The chart shows the overall debt burden in the pharmaceutical industry, providing context for assessing the company's financial strategy during its long and risky clinical research journey.
Debt to book value of all companies in the market
ESSA Pharma Inc. is a clinical-stage pharmaceutical company focused on prostate cancer treatment. Its future depends on the success of clinical trials. This chart clearly shows that for companies whose value lies in intellectual property, the debt market is closed. Financing is only possible through equity.
P/E of the company, segment and market as a whole
P/E - ESSA Pharma Inc.
For ESSA Pharma, an oncology company focused on prostate cancer, the P/E ratio is irrelevant. It has no stable profitability. Its valuation on this chart is arbitrary. Its true value is determined by the potential of its scientific developments and investors' confidence in the success of clinical trials.
P/E of the market segment - Cancer women
ESSA Pharma is a clinical-stage pharmaceutical company specializing in the development of drugs for the treatment of prostate cancer. This chart shows the average valuation for the sector, providing investors with context for assessing ESSA Pharma's scientific focus and risks.
P/E of the market as a whole
ESSA Pharma is a biopharmaceutical company specializing in the development of drugs for the treatment of prostate cancer. Its valuation is entirely dependent on the success of its drugs in clinical trials and regulatory approval. Overall market sentiment, reflected in this chart, is completely irrelevant to the company.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company ESSA Pharma Inc.
ESSA Pharma is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of prostate cancer. This chart reflects investor expectations for its innovative approach to blocking the N-terminal domain of the androgen receptor. The valuation is contingent on the success of its clinical trials.
%20P%2FE%20ESSA%20Pharma%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-ESSA-Pharma-Inc.&v=1772584772089 "Chart of the company's future (projected) P/E ESSA Pharma Inc.")
Future (projected) P/E of the market segment - Cancer women
ESSA Pharma is a clinical-stage pharmaceutical company focused on developing drugs for the treatment of prostate cancer. Its valuation relative to other oncology biotechs reflects investors' opinion of its unique approach to androgen receptor blockade, a bet that its technology will prove effective for patients.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-women&v=1772584772107 "Future (projected) P/E graph of the market segment - Cancer women")
Future (projected) P/E of the market as a whole
ESSA Pharma is a biopharmaceutical company developing drugs for the treatment of prostate cancer. Its developments are based on a novel mechanism of action, which could be a breakthrough. This chart shows the overall risk appetite of investors. For biotech companies working on innovative but risky projects, positive market sentiment is crucial for attracting funding.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772584772129 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit ESSA Pharma Inc.
ESSA Pharma is a clinical-stage biopharmaceutical company focused on developing a new class of drugs for the treatment of prostate cancer. The financial indicators reflected here represent investments in clinical research. The success of its unique approach will determine the company's future.
Profit of companies in the market segment - Cancer women
ESSA Pharma is an oncology company focused on prostate cancer treatment. This chart shows the overall profitability of the male cancer treatment sector. It helps assess how competitive the field is and which treatment approaches (hormonal, chemotherapy, targeted) are the most commercially successful.
Overall market profit
ESSA Pharma is a biopharmaceutical company developing drugs for the treatment of prostate cancer. Its success depends entirely on the results of clinical trials and FDA approval. The demand for effective cancer drugs is not dependent on economic cycles, so this timeline is irrelevant for EPIX.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company ESSA Pharma Inc.
ESSA Pharma is a biotech company developing drugs to treat prostate cancer. Its future profit forecast depends on the success of its lead drug candidate in clinical trials. This chart shows how analysts assess the potential of its innovative approach to treating this disease.
%20profit%20of%20the%20company%20ESSA%20Pharma%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-ESSA-Pharma-Inc.&v=1772584772189 "Graph of future (projected) profit of the company ESSA Pharma Inc.")
Future (predicted) profit of companies in the market segment - Cancer women
ESSA Pharma is a biopharmaceutical company developing next-generation drugs for the treatment of prostate cancer. Their technology targets the N-terminal domain of the androgen receptor. This graph shows forecasts for this segment, illustrating how scientific innovation is addressing the problem of drug resistance in oncology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-women&v=1772584772200 "Graph of future (predicted) profits of companies in a market segment - Cancer women")
Future (predicted) profit of the market as a whole
For ESSA Pharma, a company developing drugs to treat prostate cancer, this schedule is important from an investment climate perspective. Optimistic economic forecasts and investor appetite for risk make it easier to raise the capital needed to conduct expensive clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772584772271 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - ESSA Pharma Inc.
ESSA Pharma is a biopharmaceutical company focused on developing drugs for prostate cancer. This figure, without revenue, is a pure measure of investor hopes for the success of its unique scientific approach.
P/S market segment - Cancer women
ESSA Pharma is a pharmaceutical company focused on developing a new class of drugs for the treatment of prostate cancer. This chart shows the average market valuation in the female and male oncology sectors. It reflects investor expectations for ESSA's innovative approach to blocking the N-terminal domain of the androgen receptor.
P/S of the market as a whole
ESSA Pharma Inc. is a clinical-stage pharmaceutical company focused on developing a new class of drugs for the treatment of prostate cancer. Its valuation is based on the potential of its breakthrough technology. This chart, reflecting current revenue estimates, highlights that investing in such companies is a bet on future scientific advances.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company ESSA Pharma Inc.
ESSA Pharma is a biopharmaceutical company developing drugs for the treatment of prostate cancer. Its valuation is based on the future potential of its lead drug candidate. The chart reflects investors' confidence in its scientific approach and ability to develop an effective treatment for this common disease.
%20P%2FS%20ESSA%20Pharma%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-ESSA-Pharma-Inc.&v=1772584772391 "The graph of the company's future (projected) P/S ESSA Pharma Inc.")
Future (projected) P/S of the market segment - Cancer women
ESSA Pharma is a pharmaceutical company specializing in the development of drugs for the treatment of prostate cancer. Its unique approach targets the N-terminal domain of the androgen receptor. This chart shows how investors view the potential of this new therapeutic strategy.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20women&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-women&v=1772584772464 "Future (projected) P/S market segment graph - Cancer women")
Future (projected) P/S of the market as a whole
This shows the overall sentiment of oncology investors. For ESSA Pharma, a company developing drugs to treat prostate cancer, this is an indicator of the investment climate. Market optimism allows it to attract funding for the development of a new class of drugs targeting the vulnerabilities of hormone-resistant tumors.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772584772557 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales ESSA Pharma Inc.
ESSA Pharma is a pharmaceutical company focused on developing a new class of drugs for the treatment of prostate cancer. This chart reflects revenue from partnerships. Future revenue is dependent on the success of clinical trials of its drugs targeting the N-terminal domain of the androgen receptor.
Sales of companies in the market segment - Cancer women
ESSA Pharma Inc. is a pharmaceutical company focused on developing a new class of drugs for the treatment of prostate cancer. This chart shows financial activity in the oncology sector. ESSA is working to develop therapies that can be effective even when existing treatments fail, addressing an important medical need.
Overall market sales
ESSA Pharma Inc. is a pharmaceutical company focused on developing drugs for the treatment of prostate cancer. Its value depends on the results of clinical trials. The overall economic situation, shown in this chart, influences the overall investment in oncology research and the strategic decisions of large pharmaceutical companies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company ESSA Pharma Inc.
ESSA Pharma is an oncology company developing prostate cancer drugs that target a novel target in the androgen receptor signaling pathway. This graph reflects analysts' expectations for the success of clinical trials of this innovative cancer treatment approach.
%20sales%20of%20the%20company%20ESSA%20Pharma%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-ESSA-Pharma-Inc.&v=1772584772871 "Schedule of future (projected) sales of the company ESSA Pharma Inc.")
Future (projected) sales of companies in the market segment - Cancer women
ESSA Pharma is a pharmaceutical company focused on developing drugs for the treatment of prostate cancer. This chart shows expectations for the oncology sector, targeting both women and men. It reflects the enormous need for new treatments for hormone-dependent tumors.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-women&v=1772584772915 "Schedule of future (projected) sales of companies in the market segment - Cancer women")
Future (projected) sales of the market as a whole
ESSA Pharma Inc. is a pharmaceutical company focused on developing a new class of drugs for the treatment of prostate cancer. Its future depends on the success of clinical trials. This schedule, reflecting the state of the economy, affects the availability of capital to finance long-term and risky oncology research that could lead to a breakthrough in treatment.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772584772922 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality ESSA Pharma Inc.
ESSA Pharma is a biopharmaceutical company developing a new generation of drugs for the treatment of prostate cancer. This chart shows the company's financial performance at the clinical trial stage. Negative values represent investments in developing a unique mechanism of action that could help patients with resistant forms of cancer.
Market segment marginality - Cancer women
ESSA Pharma is a pharmaceutical company focused on developing drugs for the treatment of prostate cancer. For a clinical-stage company, this chart is important as an indicator of potential. It reflects the average profitability in the oncology sector, which ESSA aims to achieve if it successfully brings its drugs to market for patients with this disease.
Market marginality as a whole
ESSA Pharma is a clinical-stage pharmaceutical company focused on developing drugs for the treatment of prostate cancer. This overall market profitability chart is irrelevant to the company. Its future depends solely on the results of clinical trials and its ability to create a new standard of care for patients.
Employees in the company, segment and market as a whole
Number of employees in the company ESSA Pharma Inc.
ESSA Pharma is a pharmaceutical company developing a new generation of drugs for the treatment of prostate cancer. This graph shows a small, scientifically focused team leading its development through clinical trials.
Share of the company's employees ESSA Pharma Inc. within the market segment - Cancer women
ESSA Pharma Inc. is focused on developing a new class of drugs for the treatment of prostate cancer. This chart shows the percentage of leading oncologists, chemists, and hormone therapy specialists working on this specific problem that the company is attracting. It reflects its concentration of unique scientific expertise in the fight against this common male disease.
Number of employees in the market segment - Cancer women
ESSA Pharma is a biopharmaceutical company focused on developing drugs for the treatment of prostate cancer. Narrow specialization allows for deep expertise. This graph shows that in oncology, it is often the focused companies that achieve the greatest progress by attracting the best scientists and doctors working on a specific problem.
Number of employees in the market as a whole
ESSA Pharma Inc. focuses on prostate cancer treatment, addressing a significant issue in men's health. Specialization in pharmaceuticals allows for focused efforts and improved results. This chart reflects the overall healthcare landscape, which is driven by the success of many such companies targeting specific diseases.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company ESSA Pharma Inc. (EPIX)
ESSA Pharma is a biotech company specializing in prostate cancer. This chart represents the net valuation of its intellectual capital. The company's value is based on market expectations for its unique scientific platform (Aniten). The chart shows how highly the market values this scientific potential and development pipeline per scientist.
%20of%20the%20company%20ESSA%20Pharma%20Inc.%20(EPIX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-ESSA-Pharma-Inc.-EPIX&v=1772584773188 "Chart of market capitalization per employee (in thousands of dollars) of the company ESSA Pharma Inc. (EPIX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer women
ESSA Pharma is a biotech company focused on prostate cancer treatment. In oncology, a company's value is directly linked to the success of clinical trials. The chart shows how investors are betting on their scientific team and unique approach to treating this common disease.
%20by%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-women&v=1772584773221 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer women")
Market capitalization per employee (in thousands of dollars) for the overall market
ESSA Pharma Inc. is a pharmaceutical company specializing in the development of drugs for the treatment of prostate cancer. This chart shows the overall market performance, highlighting the importance of developments in this specific area of oncology.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772584773273 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company ESSA Pharma Inc. (EPIX)
ESSA Pharma is a clinical-stage biotech company focused on prostate cancer. The company has no commercial products. This chart shows the net loss per employee. It reflects how much the company invests in each scientist for R&D.
%20Chart%20ESSA%20Pharma%20Inc.%20(EPIX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-ESSA-Pharma-Inc.-EPIX&v=1772584773309 "Company Profit Per Employee (in thousands of dollars) Chart ESSA Pharma Inc. (EPIX)")
Profit per employee (in thousands of dollars) in the market segment - Cancer women
ESSA Pharma Inc. is a pharmaceutical company developing drugs for the treatment of prostate cancer. Being in clinical trials, it is likely to report negative earnings per employee. This metric reflects the high investment in its scientific team and long-term research, which is typical for biotech companies in this phase of development.
%20in%20the%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-women&v=1772584773362 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer women")
Profit per employee (in thousands of dollars) for the market as a whole
ESSA Pharma (EPIX) is a clinical-stage biotech company developing small-molecule drugs that block the N-terminal domain of the androgen receptor for the treatment of prostate cancer. This is an R&D business. This chart shows the market average dollar return per employee. For EPIX (which is not yet profitable), this is a benchmark: in biotech, IP can significantly exceed this average.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772584773399 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee ESSA Pharma Inc. (EPIX)
ESSA Pharma is a clinical-stage biopharmaceutical company focused on prostate cancer treatment. This chart is a glimpse into the future. Low current values are normal for biotech companies, but they could change dramatically if clinical trials are successful and the drug is approved.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-ESSA-Pharma-Inc.-EPIX&v=1772584773413 "Sales chart per company employee ESSA Pharma Inc. (EPIX)")
Sales per employee in the market segment - Cancer women
ESSA Pharma is a clinical-stage biotech company focused on prostate cancer treatment. Revenue is not yet available. This chart shows the average revenue per employee in the segment, which serves as a benchmark for commercial pharmaceutical companies. It provides context for assessing the effectiveness of ESSA's staff within the industry.
Sales per employee for the market as a whole
ESSA Pharma is a clinical-stage biotech company focused on developing drugs for the treatment of prostate cancer. The company has no commercial products or revenue, which is irrelevant. Its true value lies in the potential of its R&D team.
Short shares by company, segment and market as a whole
Shares shorted by company ESSA Pharma Inc. (EPIX)
ESSA Pharma is a biotech company developing drugs to treat prostate cancer. It's a huge but highly competitive market. This chart shows the odds that their drug will fail. The "bears" believe their scientific approach won't prove superior to existing treatments in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-ESSA-Pharma-Inc.-EPIX&v=1772584773457 "Short Shares Chart for the Company ESSA Pharma Inc. (EPIX)")
Shares shorted by market segment - Cancer women
ESSA Pharma Inc. (EPIX) is a biopharmaceutical company specializing in the treatment of prostate cancer. They are developing drugs that block the N-terminal domain of the androgen receptor. This chart reflects the total short position in the biotech sector. High values indicate general investor skepticism about the success of risky clinical trials in oncology.
Shares shorted by the overall market
ESSA Pharma is a clinical-stage biotech focused on a novel prostate cancer treatment mechanism. This chart reflects general fear. When investors are afraid, they are reluctant to bet on breakthrough but unproven drugs. The risk of clinical trial failure (binary risk) forces them to sell off EPIX shares without waiting for news.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator ESSA Pharma Inc. (EPIX)
ESSA Pharma is a biotech company focused on developing a new class of drugs to treat prostate cancer. This is a binary bet on the success of their trials. This chart measures the market "temperature," showing when the stock is "overheated" (above 70) in anticipation of a breakout or "oversold" (below 30) due to delays or setbacks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-ESSA-Pharma-Inc.-EPIX&v=1772584773510 "RSI 14 indicator chart for the company's stock ESSA Pharma Inc. (EPIX)")
RSI 14 Market Segment - Cancer women
ESSA Pharma is a pharmaceutical company specializing in the development of drugs for the treatment of prostate cancer, particularly castration-resistant prostate cancer. This chart measures the collective excitement in the oncology biotech sector. It helps determine whether the entire speculative segment is overheated by expectations.
RSI 14 for the overall market
For ESSA Pharma, a biotech company in R&D, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the cash spigot is turned off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast EPIX (ESSA Pharma Inc.)
ESSA Pharma is a biotech company focused on prostate cancer treatment. Its drug (EPI-7386) targets the N-terminal domain of the androgen receptor. This chart shows the average analyst forecast. Their targets are based on clinical data (especially in combinations) and the potential of this novel mechanism.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-EPIX-ESSA-Pharma-Inc.&v=1772584773606 "A chart showing analyst consensus forecasts for the expected stock price. EPIX (ESSA Pharma Inc.)")
The difference between the consensus estimate and the actual stock price EPIX (ESSA Pharma Inc.)
ESSA Pharma is a biotech company focused on developing a new class of drugs for the treatment of prostate cancer by blocking the N-terminal domain of the androgen receptor. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and the forecast, reflecting their faith in this complex science.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-EPIX-ESSA-Pharma-Inc.&v=1772584773655 "A chart showing the difference between the consensus forecast and the actual stock price. EPIX (ESSA Pharma Inc.)")
Analyst consensus forecast for stock prices by market segment - Cancer women
ESSA Pharma is a biotech company focused on prostate cancer treatment. It develops drugs that block the N-terminal domain of the androgen receptor. This chart shows overall expectations for the oncology sector. It reflects whether experts believe a breakthrough in the treatment of hormone-dependent cancers is possible.
Analysts' consensus forecast for the overall market share price
ESSA Pharma (EPIX) is a biopharmaceutical company focused on "invulnerable" cancers. They are developing a drug that blocks the N-terminal domain of the androgen receptor, the main cause of prostate cancer resistance. This chart shows the overall risk appetite, reflecting the market's willingness to fund breakthrough but high-risk R&D projects.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index ESSA Pharma Inc.
ESSA Pharma is a biotech company hunting prostate cancer. Their specialty is N-terminal antagonists: a new class of drugs that attack the androgen receptor (the fuel for cancer) differently than existing drugs. This chart is a pure indicator of their R&D. Its dynamics depend entirely on their (very risky) clinical trial data and their race against competitors.
AKIMA Market Segment Index - Cancer women
ESSA Pharma (EPIX) is a biopharmaceutical company specializing in prostate cancer. They are developing antigens—drugs that attack the androgen receptor (a key driver of the disease) in a novel way. This chart shows the segment's average index. It helps investors assess how EPIX's risks in this competitive field compare to the average.
The AKIM Index for the overall market
ESSA Pharma is a pharmaceutical company developing new treatments for prostate cancer resistant to standard therapy. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this specialized oncology company compares to overall economic trends.
